source
- Eli Lilly's retatrutide shows strong weight loss but no clear heart risk reduction in Phase 3 trialEli Lilly released new data from a Phase 3 trial of retatrutide, its next‑generation obesity drug. The study enrolled nearly 2,000 participants with severe obesity and existing heart disease, some…
- Scancell to list on Nasdaq after reverse merger with Neuphoria, funds $89M for melanoma immunotherapy trialScancell announced that it will become a publicly traded company on Nasdaq after completing an all‑stock reverse merger with Neophobia Therapeutics. The transaction gives Scancell a new ticker, SCL…Fierce Biotech · 22d agoDealPositive